After presenting data from a phase 1 study at a medical conference, shares of Radius Health (NASDAQ: RDUS) , a commercial-stage biotech focused on osteoporosis and cancer, rose 15% as of 11:15 a.m.

BOSTON, March 24, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided an update on the abaloparatide asset including regulatory progress as well as U.S.

Clinical-stage biotech Radius Health headed for Wall Street back in 2012, hat-in-hand, expecting the exciting prospects of its potentially best-in-class experimental osteoporosis drug would land it a ...

Investors of Radius Health (NASDAQ: RDUS) may be a bit confused Thursday after the company reported positive data in two phase 1 trials of a clinical asset aimed at treating breast cancer, but its ...

According to financial terms announced Thursday, Gurnet Point Capital and Patient Square Capital will acquire all Radius shares for $10 each. That price is a 12.2% premium to Radius’s closing stock ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Radius Health Inc. has managed ...

Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Radius Recycling Fourth Quarter 2023 Earnings Release Call and Webcast. At this time, all participants are in a ...

Every so often, a biotech company takes a hit on some news that seems negative, and at first glance is, but is likely only temporary in terms of impact. In other words, a bit of information that ...

Shares fall after the company reports a larger-than-expected quarterly loss, but exciting times lie ahead. Radius Health reported a net loss of $56.9 million for the quarter, or $1.32 per share. This ...

Traders cheer after the company presents encouraging clinical data at a medical conference. Radius Health presented data from its phase 1 005 trial at the 2017 San Antonio Breast Cancer Symposium.